Skip to Content
Søg Menu

Significantly improved pathological complete response with nivolumab + chemotherapy in NSCLC

Jonathan Spicer, Assistant Professor of Surgery, McGill University, Montreal General Hospital, presents in this MEDtalk the results from CheckMate 816, a randomized phase 3 study of neoadjuvant NIVO + chemo vs chemo in resectable NSCLC.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

CheckMate 227: 6-års data om behandling af lokalt avanceret NSCLC med Opdivo og Yervoy 

/ BestPractice Nordic
WCLC23NSCLCLungecancer

Adjuverende behandling med 3. generations EGFR-TKI kan øge progressionsfri overlevelse 

/ BestPractice Nordic
WCLC23NSCLCLungecancer

WCLC 2023 – NSCLC: Nye data på perioperativ behandling med immunterapi  

/ BestPractice Nordic
WCLC23NSCLCLungecancerImmunterapi
Tejas Patil

Exceptional Response of Lorlatinib and Cabozantinib Combination in ROS1-Rearranged NSCLC

/ Tejas Patil
NSCLC Play the Video 07:11
Timothy F. Burns

Osimertinib for the Treatment of EGFR-Mutant NSCLC in the Adjuvant Setting

/ Timothy F. Burns
NSCLC Play the Video 10:15
Birgitte Bjørnhart

Real-World Studies Highlight NSCLC Data Gaps and Survival Differences from Randomized Controlled Trials

/ Birgitte Bjørnhart
DSKO23NSCLCLungecancer Play the Video 5:04
Astrid Telhaug Karlsson

Survival Rates for Patients with NSCLC with Brain Metastases following Whole Brain Radiotherapy

/ Astrid Telhaug Karlsson
ELCC23NSCLCLungecancer Play the Video 3:22
Niels Reinmuth

Current Aspects in Early-Stage NSCLC – Perspectives from ELCC23

/ Niels Reinmuth
ELCC23NSCLCLungecancer Play the Video 3:54
Siow Ming Lee

First-line atezolizumab treatment significantly improves overall survival in patients with NSCLC and not eligible for a platinum-containing regimen

/ Siow Ming Lee
ESMO22NSCLCLungecancer Play the Video 5:14
Back to top